ODN 1826 Sodium (CpG 1826 Sodium)

About the Target

ODN 1826 sodium (CpG 1826 sodium) is a synthetic CpG oligodeoxynucleotide and agonist of TLR9 signaling pathway, that induces G1-phase arrest and apoptosis in A20 lymphoma cells while stimulating NO and iNOS production in mouse models, as part of its immunostimulatory activity. The mapped target for this entry is Toll-like receptor 9 (TLR9). For these entries, interpretation usually centers on how the material affects assay conditions or functional biology rather than on exclusive engagement of a single genetically defined receptor or enzyme. Across mechanistic studies, investigators commonly track acute pathway activation, receptor trafficking, and downstream transcriptional changes. In practical terms, the product supports reproducible workflows in which matched preparation conditions are central to interpretation.

Research Context

As an agonist-format peptide, it is typically used to trigger pathway activation on demand and to compare acute signaling events with longer adaptive changes such as receptor desensitization or altered transcriptional output. In practice, preparation, concentration, contact time, and matched workflow controls are important for separating material effects from biological signal.

• maintain matched workflow conditions so changes in assay background are not mistaken for target biology
• interpret results at the functional or systems level rather than as evidence of exclusive single-target binding
• use consistent preparation, exposure, and handling steps across comparative experiments

Experimental interpretation should therefore connect early pathway changes with later phenotypic outputs, rather than relying on a single endpoint in isolation.

Format Considerations

For routine mechanistic work, the unmodified catalog format provides a consistent starting point for concentration-response studies, benchmark experiments, and orthogonal validation. In comparative workflows, keeping the listed sodium format constant across comparator groups can reduce avoidable formulation-related differences. This is particularly helpful for comparative experiments, benchmark studies, and orthogonal validation in which small differences in formulation or handling can complicate interpretation. For peptide-centered workflows, conclusions are usually strongest when biological readouts are paired with consistent preparation and appropriately matched reference conditions.